{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:22:12Z","timestamp":1750537332613},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Myeloid sarcoma (MS) is a rare entity, and FDG PET\/CT is a useful tool for staging at diagnosis and response assessment. We present a case of a 72-year-old woman diagnosed with multifocal extramedullary MS, using FDG PET\/CT to guide palliative radiotherapy to 13 sites of disease over 2 separate relapses with complete and durable local responses and minimal toxicity. This case represents the largest reported burden of disease in MS successfully treated with FDG PET\/CT-guided radiotherapy.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003238","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T21:25:03Z","timestamp":1601501103000},"page":"886-887","source":"Crossref","is-referenced-by-count":1,"title":["18F-Fluorodeoxyglucose PET\/CT-Guided Palliative Radiotherapy Provides Durable Responses to Over a Dozen Sites of Disease in Relapsed Myeloid Sarcoma"],"prefix":"10.1097","volume":"45","author":[{"given":"Charles","family":"Shuttleworth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva A.","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giselle","family":"Kidson-Gerber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"issue":"suppl 1","key":"bib2-20230925","first-page":"1594","article-title":"Role of 18F-FDG PET\/CT in detection of disease burden and response assessment in patients with myeloid sarcoma","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3324\/haematol.2011.045047","article-title":"18F-FDG-PET\/CT for detection of extramedullary acute myeloid leukemia","volume":"96","year":"2011","journal-title":"Haematologica"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2214\/AJR.11.7743","article-title":"Utility of FDG PET\/CT in the assessment of myeloid sarcoma","volume":"198","year":"2012","journal-title":"Am J Roentgenol"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.leukres.2010.04.017","article-title":"FDG-PET is effective in the detection of granulocytic sarcoma in patients with myeloid malignancy","volume":"34","year":"2010","journal-title":"Leuk Res"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ejh.12085","article-title":"Extramedullary disease in patients with acute myeloid leukemia assessed by (18)F-FDG PET","volume":"90","year":"2013","journal-title":"Eur J Haematol"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/1748-717X-8-245","article-title":"Clinicopathologic features and responses to radiotherapy of myeloid sarcoma","volume":"8","year":"2013","journal-title":"Radiat Oncol"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.ijrobp.2011.02.057","article-title":"Radiation therapy for chloroma (granulocytic sarcoma)","volume":"82","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1182\/blood-2011-04-347229","article-title":"How I treat extramedullary acute myeloid leukemia","volume":"118","year":"2011","journal-title":"Blood"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:17:49Z","timestamp":1695622669000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":8,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003238","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,18]]}}}